Soleno reports preliminary FY2025 VYKAT XR revenue $189M-$191M; profitable

SOLENO THERAPEUTICS INC

2025-FY EPS reported $0.39 revenue$190,405,000

Preliminary Q4 2025 net revenue $90M-$92M; full-year net revenue $189M-$191M.
1,250 patient start forms since launch (207 in Q4), ~12.5% of U.S. PWS addressable market.
630 unique prescribers, 136 new in Q4; discontinuation rate ~12% for adverse events.
Achieved profitability and positive cash flow; year-end cash ~$500M after $100M buyback.
Company responded to EMA Day 120 questions; ~60% of total lives covered.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.